Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer
暂无分享,去创建一个
[1] W. Yeo,et al. Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy , 2018, Cancer management and research.
[2] O. Bruyère,et al. Skeletal health in breast cancer survivors. , 2017, Maturitas.
[3] F. Mo,et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy , 2017, BMC Women's Health.
[4] Jie He,et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[5] W. Yeo,et al. Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles , 2015, PloS one.
[6] G. Colditz,et al. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Yeo,et al. Risk factors and natural history of breast cancer in younger Chinese women. , 2014, World journal of clinical oncology.
[8] C. Blomqvist,et al. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy , 2014, Acta oncologica.
[9] A. Partridge,et al. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. , 2013, Journal of thoracic disease.
[10] M. Gnant,et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? , 2012, Cancer treatment reviews.
[11] E. Winer,et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. , 2011, European journal of cancer.
[12] D. Cameron,et al. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? , 2010, Breast Cancer Research and Treatment.
[13] S. Cremers,et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. , 2010, The Journal of clinical endocrinology and metabolism.
[14] Janet E Brown,et al. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer , 2010 .
[15] L. Melton,et al. A reference standard for the description of osteoporosis. , 2008, Bone.
[16] S. Silverman,et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[17] S. Swain,et al. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Bilezikian,et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[19] C. Blomqvist,et al. Short-Term Intermittent Intravenous Clodronate in the Prevention of Bone Loss Related to Chemotherapy-Induced Ovarian Failure , 2004, Breast Cancer Research and Treatment.
[20] W. Sauerbrei,et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) , 2003, Osteoporosis International.
[21] P. Pietschmann,et al. [Osteoporosis in premenopausal women]. , 2002, Wiener medizinische Wochenschrift.
[22] C. Blomqvist,et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. , 2001, European journal of cancer.
[23] J. Manola,et al. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. Blomqvist,et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Hart,et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. , 1990, British Journal of Cancer.